High-dose dexamethasone for prevention of cis-platin-induced vomiting.

abstract：:Leucovorin requirements for protection of the T cell line CCRF-CEM and the B cell line LAZ-007 against the cytotoxic effects of a variety of antifolates were studied. Differential leucovorin protection for DDMP-induced growth suppression occurred in the opposite direction to that for MTX, with CCRF-CEM requiring less ...

journal_title：Cancer chemotherapy and pharmacology

authors： Browman GP,Spiegl P,Booker L,Rosowsky A

更新日期：1985-01-01 00:00:00

abstract：:We have previously reported that multidrug (MDR)-reversal activity can be exerted by compounds in which two ring structures of certain types are connected by one alkyl bridge to a secondary or tertiary amine group. In the present investigation we studied the MDR-reversal activity of compounds in which the two ring str...

journal_title：Cancer chemotherapy and pharmacology

authors： Ramu A,Ramu N

更新日期：1994-01-01 00:00:00

abstract：PURPOSE:Thalidomide, originally developed as a sedative, was subsequently identified to have antiangiogenic properties. Lenalidomide is an antiangiogenic and immunomodulatory agent that has been utilized in the treatment of patients with brain tumors. We studied the pharmacokinetics and cerebrospinal fluid (CSF) penetr...

journal_title：Cancer chemotherapy and pharmacology

authors： Muscal JA,Sun Y,Nuchtern JG,Dauser RC,McGuffey LH,Gibson BW,Berg SL

更新日期：2012-04-01 00:00:00

abstract：:KW-2149, a new mitomycin C (MMC) derivative, inhibited the growth of murine P388 leukemia in vitro at 20-fold lower concentrations than those of MMC. KW-2149 was also effective in inhibiting the growth of MMC-resistant P388 (P388/MMC) cells. To elucidate these characteristics of KW-2149, its uptake and efflux were com...

journal_title：Cancer chemotherapy and pharmacology

authors： Kobayashi E,Okabe M,Kono M,Arai H,Kasai M,Gomi K,Lee JH,Inaba M,Tsuruo T

更新日期：1993-01-01 00:00:00

abstract：:The primary development of clinical resistance to 1-beta-D-arabinofuranosyl cytosine (ara-C) in leukemic blast cells is expressed as decreased cellular concentrations of its active anabolite. Correlations exist between the cellular concentrations of 1-beta-D-arabinofuranosyl cytosine 5'-triphosphate (ara-CTP) in leuke...

journal_title：Cancer chemotherapy and pharmacology

authors： Avramis VI,Mecum RA,Nyce J,Steele DA,Holcenberg JS

更新日期：1989-01-01 00:00:00

abstract：:A total of 22 relapsed or refractory ovarian cancer patients were treated with ifosfamide-containing polychemotherapy. Kinetic analyses were done to evaluate the tumor-cell-recruiting potential of the alkylating agent. Our study shows that ifosfamide can enhance tumor proliferative activity in pretreated ovarian cance...

journal_title：Cancer chemotherapy and pharmacology

authors： Rosso R,Alama A,Repetto L,Conte PF

更新日期：1990-01-01 00:00:00

abstract：:The prediction of tumor resistance to antineoplastic drugs remains an important challenge in cancer chemotherapy. Several methods have been proposed in this connection, but they present a number of problems such as clinical relevance and applicability. In the present work we put forward an original methodology to asse...

journal_title：Cancer chemotherapy and pharmacology

authors： Pauwels O,Kiss R

更新日期：1995-01-01 00:00:00

abstract：:Sixty-seven patients with acute nonlymphoblastic leukemia (ANLL) and above the age of 60 years were randomly allocated to treatment with either prednimustine + vincristine or cycles with cytosine arabinoside and thioguanine. Of the 67 patients, 13 (19%) entered a complete remission and four a partial remission. Of 33 ...

journal_title：Cancer chemotherapy and pharmacology

authors： Lönnqvist B,Andersson B,Björkholm M,Engstedt L,Gahrton G,Hast R,Holm G,Killander A,Lantz B,Lockner D,Mellstedt H,Palmblad J,Paul C,Peterson C,Simonsson B,Stalfelt AM,Udén AM,Wadman B,Oberg G

更新日期：1982-01-01 00:00:00

abstract：PURPOSE:The platinum agent oxaliplatin could be useful in treatment of cancer in pregnant women, but it is fetotoxic in rats and its effect on the human fetus is unknown. METHODS:Oxaliplatin was administered to a 25-year-old pregnant woman with metastatic rectal cancer from 20 to 30 weeks gestational age as part of th...

journal_title：Cancer chemotherapy and pharmacology

authors： Gensheimer M,Jones CA,Graves CR,Merchant NB,Lockhart AC

更新日期：2009-01-01 00:00:00

abstract：:The cytotoxicity of cisplatin alone and in combination with topotecan (TPT) or SN-38, two novel topoisomerase I (topo I) inhibitors, was determined in a panel of eight well-characterized human solid-tumor cell lines. Interactions between cisplatin and these topo I inhibitors were investigated using three different adm...

journal_title：Cancer chemotherapy and pharmacology

authors： Ma J,Maliepaard M,Nooter K,Boersma AW,Verweij J,Stoter G,Schellens JH

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:Older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome have often been excluded from myeloablative-conditioning regimens containing busulfan because of non-disease-related morbidity and mortality. We hypothesized that busulfan clearance (BuCL) in older patients (>60 years) would be reduce...

journal_title：Cancer chemotherapy and pharmacology

authors： Beumer JH,Owzar K,Lewis LD,Jiang C,Holleran JL,Christner SM,Blum W,Devine S,Kolitz JE,Linker C,Vij R,Alyea EP,Larson RA,Ratain MJ,Egorin MJ

更新日期：2014-11-01 00:00:00

abstract：PURPOSE:In TFK-1 and EGI-1 cholangiocarcinoma cell lines, zoledronic acid (ZOL) determines an S-phase block without apoptosis. Here, we investigated the occurrence of apoptosis stigmata when ZOL is associated to the BH3-mimetic ABT-737. METHODS:In EGI-1 and TFK-1 cholangiocarcinoma cell lines untreated or treated with...

journal_title：Cancer chemotherapy and pharmacology

authors： Romani AA,Desenzani S,Morganti MM,Baroni MC,Borghetti AF,Soliani P

更新日期：2011-03-01 00:00:00

abstract：PURPOSE:Paclitaxel and docetaxel are two taxanes approved for the treatment of non-small-cell lung cancer (NSCLC). However, there is limited evidence regarding the efficacy of docetaxel in NSCLC previously treated with a paclitaxel-platinum doublet (PP). The aim of our study was to evaluate the response to docetaxel in...

journal_title：Cancer chemotherapy and pharmacology

authors： Macedo-Pérez EO,Morales-Oyarvide V,Mendoza-García VO,Dorantes-Gallareta Y,Flores-Estrada D,Arrieta O

更新日期：2014-10-01 00:00:00

abstract：PURPOSE:Ifosfamide is a cornerstone of chemotherapy in bone and soft-tissue sarcoma. Results of pharmacokinetic studies indicate that the optimal schedule of ifosfamide should be repeated doses over several days. With the development of 5-day infusion devices, we developed and evaluated a 5-day infusion regimen of ifos...

journal_title：Cancer chemotherapy and pharmacology

authors： Coriat R,Mir O,Camps S,Ropert S,Billemont B,Leconte M,Larousserie F,Anract P,Alexandre J,Goldwasser F

更新日期：2010-02-01 00:00:00

abstract：PURPOSE:This dedicated QTc study was designed to evaluate the effect of the mammalian target of rapamycin inhibitor, ridaforolimus, on the QTc interval in patients with advanced malignancies. METHODS:We conducted a fixed-sequence, single-blind, placebo-controlled study. Patients (n = 23) received placebo on day 1 and ...

journal_title：Cancer chemotherapy and pharmacology

authors： Lush RM,Patnaik A,Sullivan D,Papadopoulos KP,Trucksis M,McCrea J,Cerchio K,Li X,Stroh M,Selverian D,Orford K,Ebbinghaus S,Agrawal N,Iwamoto M,Wagner JA,Tolcher A

更新日期：2012-10-01 00:00:00

abstract：PURPOSE:A metronomic schedule of chemotherapy (resulting in a greater frequency of drug delivery) has shown efficacy in head and neck cancer. Our aim was to investigate the overall survival in tongue cancer patients with metronomic neoadjuvant chemotherapy with bleomycin compared to those with surgery alone. METHODS:I...

journal_title：Cancer chemotherapy and pharmacology

authors： Kina S,Nakasone T,Kinjo T,Maruyama T,Kawano T,Arasaki A

更新日期：2016-10-01 00:00:00

abstract：PURPOSE:The ErbB family members are protein tyrosine kinases, which play a crucial role in the signal transduction pathways that regulate key cellular functions. Overexpression of the ErbB family members is associated with oncogenicity, metastatic potential, cell proliferation, apoptosis, angiogenesis, and prognosis in...

journal_title：Cancer chemotherapy and pharmacology

authors： Fu XH,Li J,Huang JJ,Zheng S,Zhang SZ

更新日期：2011-12-01 00:00:00

abstract：PURPOSE:Arsenic compounds have been found to be effective in the treatment of acute promyelocytic leukemia through the downregulation of bcl-2 expression. Resistant ovarian cancer cells often overexpress bcl-2 or p53 proteins or both. We hypothesized that arsenic compounds, such as As2O3 and As2S3, could also be active...

journal_title：Cancer chemotherapy and pharmacology

authors： Du YH,Ho PC

更新日期：2001-06-01 00:00:00

abstract：PURPOSE:Trifluorothymidine (TFT) is a fluoropyrimidine that is part of the novel combination metabolite TAS-102, in which TFT is combined with a potent thymidine phosphorylase inhibitor (TPI). TAS-102 is currently tested as an orally chemotherapeutic agent in different schedules in a phase I study. In its monophosphate...

journal_title：Cancer chemotherapy and pharmacology

authors： Temmink OH,Hoogeland MF,Fukushima M,Peters GJ

更新日期：2006-01-01 00:00:00

abstract：:The pharmacokinetics of soluble oral prednisolone were studied during induction therapy in six children with acute lymphoblastic leukaemia. There was a three- to four-fold variation in the pharmacokinetics of total and free prednisolone. For total prednisolone, the mean elimination half-life was relatively short (1.37...

journal_title：Cancer chemotherapy and pharmacology

authors： Choonara I,Wheeldon J,Rayner P,Blackburn M,Lewis I

更新日期：1989-01-01 00:00:00

abstract：PURPOSE:The safety and efficacy of oral metronomic low-dose treosulfan chemotherapy in combination with the cyclooxygenase-2 (COX-2) inhibitor rofecoxib as a compound with antiangiogenic potential, a therapeutic regimen optimally targeting endothelial cells instead of tumor cells, were assessed in pretreated advanced m...

journal_title：Cancer chemotherapy and pharmacology

authors： Spieth K,Kaufmann R,Gille J

更新日期：2003-11-01 00:00:00

abstract：PURPOSE:The ERCC1-XPF 5'-3' DNA endonuclease complex is involved in the nucleotide excision repair pathway and in the DNA inter-strand crosslink repair pathway, two key mechanisms modulating the activity of chemotherapeutic alkylating agents in cancer cells. Inhibitors of the interaction between ERCC1 and XPF can be us...

journal_title：Cancer chemotherapy and pharmacology

authors： Ciniero G,Elmenoufy AH,Gentile F,Weinfeld M,Deriu MA,West FG,Tuszynski JA,Dumontet C,Cros-Perrial E,Jordheim LP

更新日期：2021-01-05 00:00:00

abstract：PURPOSE:In gemcitabine-pretreated pancreatic cancer, salvage chemotherapy has not been established, and the prognostic factors are not completely known. The purpose of this study was to determine the efficacy and safety of infusional 5-fluorouracil (5-FU), doxorubicin, and mitomycin-C (iFAM) in patients with gemcitabin...

journal_title：Cancer chemotherapy and pharmacology

authors： Lim KH,Kim TY,Lee KH,Han SW,Oh DY,Im SA,Kim TY,Bang YJ

更新日期：2011-10-01 00:00:00

abstract：:To evaluate the value of beta-2-microglobulin as an indicator of acute and long-term cis-platinum-induced nephrotoxicity, 51Cr-EDTA clearance and serum concentration and urinary excretion of beta-2-microglobulin were measured in 18 patients treated with a regimen including cis-platinum. Before treatment all values wer...

journal_title：Cancer chemotherapy and pharmacology

authors： Sørensen PG,Nissen MH,Groth S,Rørth M

更新日期：1985-01-01 00:00:00

abstract：:The risk of potential drug-drug interactions (PDI) is poorly studied in oncology. We included 105 patients with advanced non-small-cell lung cancer (NSCLC), 100 patients with advanced breast cancer (BC) and 100 patients of the palliative care unit (PCU) receiving systemic palliative treatment between 2010 and 2015. Al...

journal_title：Cancer chemotherapy and pharmacology

authors： Hoemme A,Barth H,Haschke M,Krähenbühl S,Strasser F,Lehner C,von Kameke A,Wälti T,Thürlimann B,Früh M,Driessen C,Joerger M

更新日期：2019-04-01 00:00:00

abstract：:The antitumor effects of human lymphoblastoid interferon (HLBI) on human renal cell carcinomas transplanted in nude mice, i.e., KU-2 and RCC-1, were investigated and compared with those on other human tumors, viz. HeLa (cervical carcinoma), KB (nasopharyngeal carcinoma), H.Ep#2 (laryngeal carcinoma), and MX-1 (breast ...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamaoka T,Takada H,Yanagi Y,Kataoka T,Sakurai Y

更新日期：1985-01-01 00:00:00

abstract：PURPOSE:To investigate any effect of a CYP3A4 inhibitor (ketoconazole) or inducer (rifampicin) on cediranib steady-state pharmacokinetics in patients with advanced solid tumours. METHODS:In two Phase I, open-label trials, patients received once-daily oral doses of cediranib alone [20 mg (ketoconazole study); 45 mg (ri...

journal_title：Cancer chemotherapy and pharmacology

authors： Lassen U,Miller WH,Hotte S,Evans TR,Kollmansberger C,Adamson D,Nielsen DL,Spicer J,Chen E,Meyer T,Brown K,Rafi R,Sawyer MB

更新日期：2013-02-01 00:00:00

abstract：:The present study was aimed at answering the question of what patients with hepatocellular carcinomas could obtain long-term benefits from resectional therapy. The 239 patients hepatectomized from 1973 through 1986, with 33 tumor-free, 3-year survivors, were the subjects of the study. The following criteria for long-t...

journal_title：Cancer chemotherapy and pharmacology

authors： Yamanaka N,Okamoto E

更新日期：1989-01-01 00:00:00

abstract：BACKGROUND:The correlation of the oncological outcomes of docetaxel and cabazitaxel in Japanese metastatic castration-resistant prostate cancer (mCRPC) patients has not been unclear. MATERIALS AND METHODS:This study included a total of 47 consecutive Japanese mCRPC patients treated with cabazitaxel and assessed the pr...

journal_title：Cancer chemotherapy and pharmacology

authors： Kosaka T,Hongo H,Watanabe K,Mizuno R,Kikuchi E,Oya M

更新日期：2018-12-01 00:00:00

abstract：PURPOSE:Ramucirumab plus docetaxel improved survival in REVEL, a randomized phase 3 trial for patients with Stage IV non-small cell lung cancer after standard platinum-based chemotherapy. This exploratory analysis evaluated the exposure-response relationship of ramucirumab from REVEL. METHODS:Patients received ramucir...

journal_title：Cancer chemotherapy and pharmacology

authors： Smit EF,Garon EB,Reck M,Cappuzzo F,Bidoli P,Cohen RB,Gao L,O'Brien LM,Lee P,Zimmermann A,Ferry DR,Melemed AS,Pérol M

更新日期：2018-07-01 00:00:00